Global CAR T Cell Therapy for Acute Lymphoblastic Leukemia (ALL) Market Scenario, 2030

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia Market Analysis, Epidemiology Insights and Forecast 2030

Acute lymphoblastic leukemia (ALL), also called as lymphoblastic leukemia, is one of the most common types of cancer, which spreads in the body through lymph nodes, spinal cord, liver, spleen, and central nervous system, among others. B-cell ALL, T-cell ALL, and Philadelphia chromosome-positive ALL (Ph+ ALL) are three of the most common primary types of ALL.

DelveInsight’s “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030” report delivers an in-depth understanding of the CAR T-Cell Therapy use for Acute Lymphoblastic Leukemia as well as the CAR T-Cell Therapy market trends for Acute Lymphoblastic Leukemia in the 6MM i.e., United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).

 

View report: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

Study Period: 2017–2030

Acute Lymphoblastic Leukemia Disease Understanding, Use of CAR-T Cell Therapies and Treatment Algorithm

Acute Lymphoblastic Leukemia and use of CAR-T Cell Therapies Overview

Chimeric antigen receptor (CAR) T-cell therapy involves genetic modification of patient’s autologous T-cells to express a CAR, specific for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient. CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signalling domains.

A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137 (Morgenstern & Irwin, 2019).

T-cell genetic modification may occur either via viral-based gene transfer methods or non-viral methods, such as DNA-based transposons, CRISPR/Cas9 technology, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), or direct transfer of in vitro transcribed-mRNA by electroporation.

Acute lymphoblastic leukemia is the most common type of childhood cancer affecting the blood and bone marrow. The main treatment for ALL in adults is typically long-term chemotherapy that takes place in three phases: induction, consolidation, and maintenance treatment.

CAR T-cells targeted to CD19 have resulted in unprecedented remission rates for adult and pediatric patients with relapsed and refractory B cell acute lymphoblastic leukemia (ALL).

 

Acute Lymphoblastic Leukemia Diagnosis

To diagnose leukemia, doctors perform a number of tests. Usually, doctors begin with a blood test (called a CBC, or complete blood count). Although the blood test may show leukemia cells, doctors need to examine a sample of bone marrow before confirming the exact diagnosis. This sample is obtained by performing a bone marrow aspirate, where doctors take a small amount of fluid from the bone marrow, where blood cells are made. Then they examine the fluid under a microscope to confirm the type of cancer before they begin treatment.

An additional test that may be performed along with the bone marrow aspirate is a bone marrow biopsy. A bone marrow biopsy may help in making a diagnosis when there are too few cells in the aspirate sample.

 

Acute Lymphoblastic Leukemia Treatment

It covers the details of conventional and current medical therapies available in the Acute Lymphoblastic Leukemia market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States and Europe.

The DelveInsight CAR-T Cell Therapy for Acute Lymphoblastic Leukemia market report gives a thorough understanding of Acute Lymphoblastic Leukemia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Acute Lymphoblastic Leukemia treatment algorithms and treatment guidelines for Acute Lymphoblastic Leukemia in the US and Europe.

Request for sample pages: https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market

Acute Lymphoblastic Leukemia CAR-T cell Therapy Chapters

Therapy chapter segment of the CAR-T Cell Therapy for Acute Lymphoblastic Leukemia report encloses the detailed analysis of Acute Lymphoblastic Leukemia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs based on CAR-T Cell therapies. It also helps to understand the Acute Lymphoblastic Leukemia CAR-T Cell therapies based clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included therapy and the latest news and press releases.

Acute Lymphoblastic Leukemia Marketed CAR-T Cell Therapies

1. Kymriah (tisagenlecleucel): Novartis

Currently, Novartis’ Kymriah (tisagenlecleucel) is the only approved therapy available in the ALL market. It is the first chimeric antigen receptor T cell (CAR-T) therapy approved. A novel immunocellular therapy and one-time treatment, Kymriah uses patient's T cells to fight cancer. With the approval of Kymriah, investors have started to shift their focus on a number of companies which have been developing their pipeline candidates to remain afloat in the highly competitive environment.

Products detail in the report…

Acute Lymphoblastic Leukemia Emerging CAR-T Cell Therapies

1. PBCAR0191: Precision BioSciences

PBCAR0191 is a novel CD19 targeted allogeneic CAR T therapy candidate being developed by Precision BioSciences for the treatment of relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL), and currently, it is in phase I/IIa clinical trial. It is the Company’s first gene-edited allogeneic anti-CD19 CAR T-cell product candidate which is being developed in collaboration with Servier.

Products detail in the report… 

Acute Lymphoblastic Leukemia CAR-T Cell Therapies Market Outlook

Click the link and read more about Market Insights of the report: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market

The Acute Lymphoblastic Leukemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Acute Lymphoblastic Leukemia market trends by analyzing the impact of current CAR-T cell therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of Acute Lymphoblastic Leukemia market trend of each marketed drug and late-stage pipeline CAR-T cell therapies by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, CAR-T Cell Therapies for Acute Lymphoblastic Leukemia market in the United States and Europe is expected to change in the study period 2017–2030.

Market Size of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia in the 6MM is expected to be USD 1,315.7 Million in 2030.

Owing to the launch of upcoming therapies, market size shall increase during forecast period (2020-2030).

Among the EU-5 countries, the Germany, France, Italy accounts for highest market size for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia followed by UK and Spain.

Acute Lymphoblastic Leukemia CAR-T Cell Therapy Pipeline Development Activities

The report provides insights into different CAR-T based therapeutic candidates in Phase II, and Phase III stage. It also analyses Acute Lymphoblastic Leukemia key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Acute Lymphoblastic Leukemia emerging CAR-T Cell therapies.

Reimbursement Scenario in Acute Lymphoblastic Leukemia CAR-T Cell Therapies

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In report we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

Visit the link and download report: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market

Related Reports:

• Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast-2030
• CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) - Market Insights and Market Forecast-2030
• Acute Lymphoblastic Leukemia (ALL) - Epidemiology Forecast to 2030
• Acute Lymphoblastic Leukemia (ALL) Pipeline Insight, 2020

About DelveInsight:

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life­­ sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.